

Metabolomics profiling reveals novel markers for leukocyte telomere length

Jonas Zierer^{1,2}, Gabi Kastenmüller^{1,2}, Karsten Suhre^{2,3}, Christian Gieger^{4,5,6}, Veryan Codd⁷, Pei-Chien Tsai¹, Jordana Bell¹, Annette Peters⁵, Konstantin Strauch⁸, Holger Schulz^{9,10}, Stephan Weidinger¹¹, Robert P. Mohney¹², Nilesh J. Samani^{7,13}, Tim Spector¹, Massimo Mangino^{1,14*}, and Cristina Menni^{1*}

¹ Department of Twin Research & Genetic Epidemiology, King's College London, London, UK

² Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München, Neuherberg, Germany

³ Department of Physiology and Biophysics, Weill Cornell Medical College in Qatar, Doha, Qatar

⁴ Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

⁵ Institute of Epidemiologie II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

⁶ German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany

⁷ Department of Cardiovascular Sciences, University of Leicester, Leicester, UK

⁸ Institute of Genetic Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany

⁹ Institute of Epidemiology I, Helmholtz Zentrum München, Neuherberg, Germany

¹⁰ Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Munich, Germany

¹¹ Department of Dermatology, Venereology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

¹² Metabolon, Inc. Durham, NC 27713, USA

¹³ National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK

¹⁴ National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St. Thomas' Foundation Trust, London, UK

* Co-senior author

Key words: telomere length, biological aging, metabolomics, glutathione, oxidative stress

Received: 10/12/15; **Accepted:** 01/17/16; **Published:** 01/20/16

Correspondence to: Cristina Menni, PhD; **E-mail:** cristina.menni@kcl.ac.uk

Copyright: Zierer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract: Leukocyte telomere length (LTL) is considered one of the most predictive markers of biological aging. The aim of this study was to identify novel pathways regulating LTL using a metabolomics approach. To this end, we tested associations between 280 blood metabolites and LTL in 3511 females from TwinsUK and replicated our results in the KORA cohort. We furthermore tested significant metabolites for associations with several aging-related phenotypes, gene expression markers and epigenetic markers to investigate potential underlying pathways. Five metabolites were associated with LTL: Two lysolipids, 1-stearoylglycerophosphoinositol ($P=1.6\times 10^{-5}$) and 1-palmitoylglycerophosphoinositol ($P=1.6\times 10^{-5}$), were found to be negatively associated with LTL and positively associated with phospholipase A2 expression levels suggesting an involvement of fatty acid metabolism and particularly membrane composition in biological aging. Moreover, two gamma-

glutamyl amino acids, gamma-glutamyltyrosine ($P=2.5 \times 10^{-6}$) and gamma-glutamylphenylalanine ($P=1.7 \times 10^{-5}$), were negatively correlated with LTL. Both are products of the glutathione cycle and markers for increased oxidative stress. Metabolites were also correlated with functional measures of aging, i.e. higher blood pressure and HDL cholesterol levels and poorer lung, liver and kidney function. Our results suggest an involvement of altered fatty acid metabolism and increased oxidative stress in human biological aging, reflected by LTL and age-related phenotypes of vital organ systems.

INTRODUCTION

Telomeres are repetitive DNA sequences located at the end of each chromatid. Several proteins, such as the telomere repeat-binding factor (TRF) 1 and 2, bind specifically to this area forming large nucleoprotein complexes, the t-loops [1]. These structures protect the DNA from degradation and end-to-end fusion. Telomeres shorten with each cell cycle, due to the inability of the DNA polymerase to replicate the end of the lagging strand. Thus, the shortening of telomeres has been proposed as a “mitotic clock” which limits the replicative life span of cells and causes cell senescence [2]. In fact, leucocyte telomere length (LTL) has been associated not only with chronological age [3] but also many aging-related diseases, such as Alzheimer’s Disease (AD) [4,5], cardiovascular disease [6,7] and cancer [8,9]. Furthermore, LTL was found to predict mortality [10,11] and longevity [12]. Thus, it was suggested as potential biomarker of biological aging [13].

Genome-wide association studies have until now identified ten genes associated with LTL [14,15,16,17]. Most of these genes physically interact with telomeres; however, how the shortening of telomeres affects an individual’s health is still not fully understood.

Recent developments in the field of metabolomics allow for the high-throughput measurement of an extensive set of low-molecular-weight molecules (metabolites) [18]. Changes in metabolite concentrations reflect physiological functions and can indicate early stages of diseases [19]. Recently, a study on LTL revealed strong associations with blood biomarkers in a cohort of American Indians [20]. However, the study was small ($n=423$) and lacked independent replication.

In this study, we assess to which extent metabolic profiles are correlated with LTL in a large population study ($n=3511$, females only) from the UK using a non-targeted metabolomics platform. We replicate our results in an independent cohort from Germany ($n=904$). Furthermore, we examine the relationship of the LTL-associated metabolites with aging-related phenotypes as well as gene expression and methylation markers in order to gain insights in the mechanisms of biological aging.

RESULTS

The demographic characteristics of the study populations are presented in Table 1. We analyzed the associations between 280 fasting blood metabolites and LTL in 3511 women from the TwinsUK cohort (see supplemental Table 1).

Table 1. Population Characteristics

	TwinsUK	KORA
<i>N</i>	3511	904
<i>Age (yrs)</i>	53.6 ± 13.6	60.5 ± 8.8
<i>MZ:DZ:Singletons*</i>	1654:1360:497	0:0:904
<i>TL</i>	3.72 ± 0.67	1.85 ± 0.31
<i>BMI (kg/m²)</i>	26.21 ± 5.14	27.87 ± 5.25
<i>FEV1 (l)</i>	2.60 ± 0.61	2.79 ± 0.50
<i>HDL (mmol/L)</i>	1.71 ± 0.48	
<i>DBP (mm Hg)</i>	78.01 ± 10.68	
<i>SBP (mm Hg)</i>	126.71 ± 18.20	
<i>ALAT (IU/L)</i>	27.63 ± 17.07	
<i>GGT (U/L)</i>	28.36 ± 25.44	
<i>eGFR (mL/min/1.73m²)</i>	83.78 ± 17.07	
<i>smoking (non:ex:current)</i>	1905:1134:447	

*MZ=monozygotic, DZ=dizygotic




Figure 1. Telomere length, metabolite and phenotype interrelationships. Nodes represent variables where rectangles represent metabolites, circles represent phenotypes, pentagons represent expression levels and hexagons represent DNA methylation levels. Links between nodes represent significant correlations (red negative, blue positive). Thicker edges indicate stronger correlations.

Table 2. Metabolites significantly associated with LTL.

Metabolite	PW	TwinsUK		KORA	Meta	
		beta [95%CI]	p	beta [95%CI]	beta [95%CI]	p
gamma-glutamyltyrosine	Peptide	-0.09 [-0.12:-0.05]	3.41×10^{-6}	-0.05 [-0.12:0.02]	-0.08 [-0.11:-0.05]	2.51×10^{-6}
1-stearoylglycerophosphoinositol	Lipid	-0.09 [-0.13:-0.05]	1.36×10^{-6}	-0.00 [-0.07:0.07]	-0.07 [-0.10:-0.04]	1.60×10^{-5}
1-palmitoylglycerophosphoinositol	Lipid	-0.08 [-0.13:-0.04]	7.36×10^{-5}	-0.07 [-0.14:0.01]	-0.08 [-0.12:-0.04]	1.64×10^{-5}
gamma-glutamyl-phenylalanine	Peptide	-0.08 [-0.12:-0.04]	2.72×10^{-5}	-0.04 [-0.11:0.02]	-0.07 [-0.10:-0.04]	1.68×10^{-5}
4-vinylphenol sulfate	Xenobiotic	-0.08 [-0.12:-0.04]	7.41×10^{-5}	-0.03 [-0.10:0.05]	-0.07 [-0.10:-0.03]	1.41×10^{-4}

We found two lipids (1-stearoylglycerophosphoinositol: Beta [95%CI] =-0.07 [-0.10:-0.04] change in metabolite z-score per change in LTL z-score, $P=1.6\times 10^{-5}$ and 1-palmitoylglycerophosphoinositol: Beta [95%CI] =-0.08 [-0.12:-0.04], $P=1.6\times 10^{-5}$), two gamma-glutamyl-amino acids (gamma-glutamyltyrosine: Beta [95%CI] =-0.08 [-0.11:-0.05], $P=2.5\times 10^{-6}$ and gamma-glutamylphenylalanine: Beta [95%CI] =-0.07 [-0.10:-0.04], $P=1.7\times 10^{-5}$), and one xenobiotic (4-vinylphenol sulfate: Beta [95%CI] =-0.07 [-0.10:-0.03], $P=1.4\times 10^{-4}$) to be negatively associated with LTL after adjustment for potential confounding factors and after correcting the results for multiple testing (Table 2, Supplemental Figure 1). All five metabolites showed the same effects with similar effect sizes in 904 female individuals from the KORA F4 study, even though they did not reach significance level. All metabolites remained Bonferroni-significant ($P<1.8\times 10^{-4}$) after meta-analysis.

Three multivariate Lasso models were fitted to predict LTL: The first using clinical variables only (age, BMI), the second using the five identified metabolites only, and the third using both clinical variables and metabolites. The model based on metabolites alone could not achieve

the performance of the model based on clinical variables alone, however, combining clinical variables with metabolites significantly improved the prediction in the combined model (Figure 2). In the combined model, 1-stearoylglycerophosphoinositol was the strongest predictor followed by the 4-vinylphenol sulfate. All five metabolites were selected in the optimal Lasso model ($\beta < 0$), suggesting non-redundant associations with LTL. The coefficient of determination, a measure of goodness of fit, of the final model was estimated at 14.5% in a leave-one-out validation.

Moreover, we found all five metabolites to be strongly associated with several aging-related phenotypes independently of chronological age (Table 3): Both lysolipids correlated with increased systolic blood pressure (1-stearoylglycerophosphoinositol: Beta=1.09 [0.56:1.61], $P=5.3\times 10^{-5}$ and 1-palmitoylglycerophosphoinositol: Beta=1.10 [0.52:1.67], $P=1.7\times 10^{-4}$). Additionally, 1-palmitoyl-glycerophosphoinositol was found to be associated with the serum concentration of gamma-glutamyl transpeptidase (GGT), a measure of liver function (Beta=0.08 [0.03:0.12], $P=1.0\times 10^{-3}$).




Figure 2. LTL prediction performance. The figure shows the prediction performance (mean square error on Y axis) of three different Lasso models, based on metabolites only (red), clinical variables only (blue) and metabolites with clinical variables combined (green), dependent on the amount of regularization (lambda on x axis).

Table 3. Phenotypes associated with LTL and associated metabolites.

	phenotype	beta [95%CI]	p
telomere length	HDL cholesterol	0.04 [0.02:0.06]	2.50×10^{-6}
	eGFR	1.42 [0.82:2.01]	2.79×10^{-6}
	smoking	-0.06 [-0.08:-0.03]	3.17×10^{-5}
	FEV1	0.03 [0.01:0.05]	8.85×10^{-4}
1-palmitoylglycerophosphoinositol	SBP	1.10 [0.52:1.67]	1.76×10^{-4}
	GGT	0.08 [0.03:0.12]	1.04×10^{-3}
1-stearoylglycerophosphoinositol	SBP	1.09 [0.56:1.61]	5.34×10^{-5}
4-vinylphenol sulfate	smoking	0.24 [0.22:0.26]	2.32×10^{-102}
	FEV1	-0.02 [-0.04:-0.01]	1.40×10^{-3}
gamma-glutamylphenylalanine	eGFR	-2.24 [-2.74:-1.73]	3.14×10^{-18}
	GGT	0.15 [0.10:0.19]	3.21×10^{-12}
	FEV1	-0.03 [-0.05:-0.02]	4.48×10^{-6}
	HDL cholesterol	-0.03 [-0.05:-0.02]	1.15×10^{-5}
	ALAT	0.10 [0.05:0.14]	5.76×10^{-5}
gamma-glutamyltyrosine	GGT	0.14 [0.10:0.19]	5.41×10^{-11}
	eGFR	-1.65 [-2.19:-1.11]	1.58×10^{-9}
	ALAT	0.11 [0.06:0.16]	1.67×10^{-5}

The two gamma-glutamyl amino acids were strongly associated with the estimated glomerular filtration rate (eGFR), a marker for renal function (gamma-glutamyltyrosine: Beta=-1.65 [-2.19:-1.11], $P=1.6 \times 10^{-9}$ and gamma-glutamylphenylalanine: Beta=-2.24 [-2.74:-1.73], $P=3.1 \times 10^{-18}$), and two markers of liver function, namely GGT and alanine amino transaminase (ALAT) (GGT: Beta=0.14 [0.10:0.19], $P=5.4 \times 10^{-11}$ and Beta=0.15 [0.10:0.19], $P=3.2 \times 10^{-12}$ respectively; ALAT: Beta=0.11 [0.06:0.16], $P=1.7 \times 10^{-5}$ and Beta=0.10 [0.05:0.14], $P=5.8 \times 10^{-5}$ respectively). Gamma-glutamylphenylalanine was additionally associated with lung function, measured as forced expiratory volume in one second (FEV1, Beta=-0.03 [-0.05:-0.02], $P=4.5 \times 10^{-6}$), and HDL cholesterol levels (Beta=-0.03 [-0.05:-0.02], $P=1.1 \times 10^{-5}$).

Moreover, the xenobiotic 4-vinylphenol sulfate was strongly associated with tobacco smoking (Beta=0.24 [0.22:0.26], $P=2.3 \times 10^{-102}$) and also weakly with FEV1 (Beta=-0.02 [-0.04:-0.01], $P=1.4 \times 10^{-3}$).

Thus, all five metabolites were consistently associated with accelerated biological aging, i.e. shorter telomeres, higher blood pressure and higher HDL cholesterol levels

and poorer lung, liver and kidney function (Table 3 and Figure 1).

To further investigate mechanisms of biological aging, we analyzed the association of the five significant metabolites with gene expression levels of related enzymes, namely GGT and phospholipase A2 (PLA2), in a subset of 753 individuals with RNA chip data from available LCL probes available. We found gamma-glutamyltyrosine was positively associated with GGT1 and GGTL3 gene expressions (probes ILMN_2274240: Beta=0.09 [0.02:0.15], $P=0.01$ and ILMN_1786186: Beta=0.07 [0.00:0.14], $P=0.04$). Also, 1-stearoylglycerophosphoinositol was positively associated with expression of the PLA2 gene PLA2G15 (probe ILMN_1756910: Beta=0.09 [0.01:0.16], $P=0.02$ and probe ILMN_1798955: Beta=0.08 [0.00:0.15], $P=0.05$) as well as 1-palmitoylglycerophosphoinositol (probe ILMN_1756910: Beta=0.08 [0.00:0.16], $P=0.05$).

The metabolite 4-vinylphenol sulfate is known to be associated with several DNA methylation probes, possibly driven by tobacco smoking [21,22]. We found one of these probes, cg19572487, being significantly

associated with LTL (Beta= 0.10 [0.04:0.17], $P=9\times 10^{-3}$), smoking (Beta=-0.51 [-0.63:-0.39], $P=9\times 10^{-16}$) and 4-vinylphenol sulfate levels (Beta=-0.05 [-0.09:-0.02], $P=1\times 10^{-3}$) in our data. The probe is located on chromosome 17 in the retinoic acid receptor, alpha (RARA) gene.

DISCUSSION

In the largest study of this kind, we searched for molecular markers and mechanisms involved in LTL regulation using a metabolomics approach. We identified five novel blood metabolites, namely gamma-glutamyltyrosine, gamma-glutamylphenylalanine, 1-stearoylglycerophosphoinositol, 1-palmitoylglycerophosphoinositol and 4-vinylphenol sulfate, independently associated with LTL with high statistical significance. These metabolites belong to three different classes: lysolipids, gamma-glutamyl amino acids and xenobiotics, which will be discussed in the following.

Lysolipids

Lysolipids are produced from glycerophospholipids by the enzyme phospholipase A2 (PLA2), which releases one of the fatty acids from the glycerol backbone [23]. Glycerophospholipids were previously found to be positively correlated with LTL [20] while in our study, circulating levels of the lysolipids 1-stearoylglycerophosphoinositol and 1-palmitoylglycerophosphoinositol were significantly associated with shortening of LTL. This suggests an increased activity of PLA2 in advanced biological aging. This hypothesis is further confirmed by the positive association of the two lysolipids with PLA2 gene expression levels in LCLs in our study. PLA2 activity, amongst others, affects the composition and physiology of cell membranes by catalyzing the hydrolysis of membrane lipids [24,25]. The integrity of cell membranes and their ability to resist oxidative stress have been shown to be key aspects of biological aging [26]. Studies comparing centenarians with younger controls identified alterations of cell membrane composition [27] and particularly depletion of the lysolipid stearylphosphatidylcholine [28] as possible reasons for longevity.

Another regulator of membrane fluidity is the saturation of fatty acids. Both stearic acid and palmitic acid are saturated fatty acids that are known to decrease membrane fluidity, which in turn was associated with increased susceptibility to disease [29,30,31]. In contrast higher levels of polyunsaturated fatty acid-containing phospholipids were observed in centenarians compared to elderly [32], suggesting their involvement in retarded biological aging. These alterations of

membrane composition with biological aging provide a possible explanation for previously reported association of LTL with e.g. AD [4].

Gamma-glutamyl amino acids

We found two gamma-glutamyl amino acids, gamma-glutamyltyrosine and gamma-glutamylphenylalanine, were negatively associated with LTL. These metabolites are components of the gamma-glutamyl cycle and are produced by the degradation of glutathione (GSH) and its conjugates catalyzed by the enzyme GGT. The main purpose of this reaction is regeneration of the intracellular GSH pool, i.e. to break-down extra-cellular GSH conjugates to make its components available for reimport into the cell [33,34,35]. GSH is crucial for detoxification of reactive oxygen species (ROS) as well as other toxic compounds [33,34,35]. Thus, increased GGT activity was proposed as a marker for increased oxidative stress [33,36]. Gamma-glutamyltyrosine and gamma-glutamylphenylalanine were both highly correlated with the abundance of the GGT enzyme, as well as GGT1 and GGTL3 gene expression in this study. The serum concentration of GGT is a common clinical marker for liver function [37]. While the liver produces most of the GSH [34], in the body GGT is most active in kidneys, which absorb GSH for detoxification [34,37]. Accordingly, we also found kidney function, measured as eGFR, being highly correlated with both, LTL and gamma-glutamyl amino acids. In conclusion, the gamma-glutamyl amino acids indicate an involvement of increased oxidative stress and worsened liver and kidney function in biological aging.

We also found gamma-glutamylphenylalanine being associated with worsened lung function in both cohorts. This might also be due to oxidative stress, which was previously associated with chronic lung disease [38].

4-Vinylphenol sulfate

4-vinylphenol sulfate is a xenobiotic that was reported to be strongly associated with tobacco smoking [39]. We observed the same correlation in our data. Moreover, we found both 4-vinylphenol sulfate as well as LTL to be strongly correlated with cotinine abundance, which is a well-established marker for tobacco smoking. Accordingly, higher levels of 4-vinylphenol sulfate were associated with worsened lung function. Moreover, analysis of DNA methylation data from our cohort confirmed previously published associations of 4-vinylphenol sulfate with the methylation level of a CpG site in the RARA gene [21] and revealed an association of the same site with LTL

and smoking. RARA is a transcription factor that was shown to regulate differentiation and apoptosis [40]. However, despite the strong correlation between LTL and smoking, we did not find a significant difference in LTL between monozygotic twins, discordant for smoking. These associations show how smoking accelerates biological aging mediated by changes in metabolism as well as DNA methylation. Smoking was shown to have a profound effect on the GSH metabolism of the lung [38], suggesting increased oxidative stress as a possible link between smoking, metabolism and LTL.

While we were able to identify five novel markers of LTL, our study has some limits. First, we analyzed data of females only and some of the identified metabolites are known to show gender-specific blood levels [41]. However, in a small pilot (n=372) from the TwinsUK cohort we observed concordant correlations between LTL and gamma-glutamyl amino acids as well as 4-vinylphenol sulfate for men as for women. In contrast, we did not see an association between any of the lysolipids and LTL in men, suggesting gender-specific changes of fatty acid metabolism with aging. Second, we did not reach statistical significance in the replication cohort. This can be attributed to smaller sample size. The power to detect the observed effects at a significance level of 0.05 in 900 individuals is only around 50%. Nonetheless, despite the lack of power, the much higher age and the different geographical location and genetic background of the replication cohort, all of the five metabolites remain Bonferroni-significant after meta-analysis.

Our results suggest two mechanisms of biological aging: On the one hand, changes in lipid metabolism and resulting changes of the cell membrane composition appear to be related to LTL and biological aging. On the other hand, we observed metabolites indicating increased oxidative stress due to alterations in the GSH metabolism, which has been previously related to LTL and aging phenotypes. One possible cause for increased oxidative stress is tobacco smoking, which might mediate the association of 4-vinylphenol sulfate with LTL. Moreover we found LTL and the related metabolites being associated with impairment of liver and kidney function. This highlights the importance of detoxification, particularly of reactive oxygen species, in biological aging.

METHODS

Discovery population. Study subjects were twins enrolled in the TwinsUK registry, a national register of adult twins recruited as volunteers without selecting for

any particular disease or trait [42]. In this study we analyzed data from 3511 female twins who had who had complete data for LTL and metabolomics profiling. The study was approved by St. Thomas' Hospital Research Ethics Committee, and all twins provided informed written consent.

Replication cohort. KORA F4 is a population cohort based in the region of Augsburg, Germany [43]. The replication set consisted of 904 female individuals with serum metabolite levels, measures of telomeres and measures of lung function [44] available.

LTL measurement. A detailed description of LTL measurement in both TwinsUK and KORA was previously described in Codd et al. [15]. In brief, mean LTL of the samples was measured using a quantitative PCR-based technique [14,45] and expressed as a ratio of telomere repeat length (T) to a copy number of a single copy gene (S). A calibrator sample or a standard curve was used for to standardize T/S results across plates. LTLs measures were inverse normalized in both cohorts.

Metabolomics measurement. Metabolomics data was measured by Metabolon Inc., Durham, USA as previously described [46]. Briefly, metabolite concentrations were measured in blood samples using an untargeted GC/MS and LC/MS platform. Measurements were scaled by run-day median and inverse normalized in both cohorts.

Aging phenotypes. Lung function was measured as forced expiratory volume in one second (FEV1) in line with ATS/ERS recommendations [44,47]. Furthermore, diastolic and systolic blood pressure (DBP and SBP), body mass index (BMI) and serum HDL cholesterol levels were measured during clinical visits of the study participants. Renal function was measured by estimating glomerular filtration rate (eGFR) from serum creatinine levels using the CKD-EPI equation [48]. Liver function was assessed by measuring serum gamma-glutamyl transpeptidase (GGT) and alanine amino transaminase (ALAT) concentrations. Both measures were inverse normalized prior to analysis.

Gene expression. RNA abundance was measured in LCLs of 778 female individuals from the TwinsUK cohort using the Illumina Human HT-12 V3 BeadChip as part of the MuTHER project as previously described [49]. We selected 30 probes from GGT and PLA2 genes. Probes were adjusted for batch effects by linear models and residuals were inverse normalized prior to analysis.

DNA methylation. DNA was extracted from whole blood, bisulfite converted and subsequently analyzed

using the Infinium 450K kit as previously described [50]. The beta mixture quantile dilation (BMIQ) method was performed to correct for technical variation [51]. Measurements were inverse normalized and then adjusted for batch effects, family structure and cell counts (PlasmaBlast, CD8+CD28-CD45RA- T cells, naive CD8 T cells, CD4+ T cells, Natural Killer cells, monocytes, and granulocytes) using linear models.

Statistical analysis. All analyses were performed using R (version 3.1.2) using the lme4 (version 1.1) package.

Correlations between metabolites and LTL were calculated using linear mixed models, correcting for age, BMI and family relatedness (as random intercept). A conservative multiple test-corrected threshold of $P < 1.8 \times 10^{-4}$ was used to identify significant associations; this value represented $P = 0.05$ divided by the total number of tests performed (280 metabolites). We replicated the five Bonferroni-significant metabolites in the KORA F4 cohort. The data was consistently normalized in both cohorts. The results were meta-analyzed using inverse variance fixed effect meta-analysis implemented in the R package meta (version 4.3).

We estimated the power of the replication cohort using the R package pwr (version 1.1), which implements power estimation according to Cohen [52].

To identify redundant associations of the metabolites, we fitted a multivariate Lasso model [53] incorporating all Bonferroni significant metabolites together with age and BMI. The predictive performance of the model was then compared to a similar model containing age and BMI only. The model performance was assessed by calculating the predicted residual sum of squares (PRESS) and subsequent P^2 statistics using a leave-one-out cross validation.

Subsequently, we aimed to further explore the relationship of LTL and the identified metabolites with biological aging. To this end, we used linear mixed models to test for association of the previously identified metabolites with previously described aging phenotypes. All models were adjusted for age, BMI and family relatedness. The lung function parameter FEV1 was additionally adjusted for height, as suggested in the literature. We replicated the associations with lung function parameters in KORA, adjusting for the same covariates.

Funding

This work was supported by the EU Framework Programme 7 small-scale focused research collaborative

project EurHEALTHaging [277849]; TwinsUK was funded by the Wellcome Trust; European Community's Seventh Framework Programme [FP7/2007-2013]. The study also receives support from the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. TDS is an ERC Advanced Researcher.

The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. This study was partly supported by the Competence Network Asthma and COPD (ASCONET), network COSYCONET (subproject 2, BMBF, FKZ 01GI0882) funded by the German Federal Ministry of Education and Research (BMBF). KS was supported by the Biomedical Research Program at Weill Cornell Medical College in Qatar, funded by the Qatar Foundation.

ACKNOWLEDGEMENTS

The authors would like to thank Alessia Visconti and Mario Falchi for their statistical advice.

Conflict of interest statement

Robert Mohny is an employee of Metabolon Inc.

REFERENCES

1. Lange T De. Shelterin: The protein complex that shapes and safeguards human telomeres. *Genes and Development*. 2005; 19:2100–2110.
2. Harley CB, Vaziri H, Counter CM, and Allsopp RC. The telomere hypothesis of cellular aging. *Experimental gerontology*. 1992; 27:375–382.
3. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, Aviv A, and Spector TD. Obesity, cigarette smoking, and telomere length in women. *Lancet*. 2005; 366:662–664.
4. Panossian L. Telomere shortening in T cells correlates with Alzheimer's disease status. *Neurobiology of Aging*. 2003; 24:77–84.
5. Thomas P, O' Callaghan NJ, and Fenech M. Telomere length in white blood cells, buccal cells and brain tissue and its variation with ageing and Alzheimer's disease. *Mechanisms of Ageing and Development*. 2008; 129:183–190.
6. Fitzpatrick AL, Kronmal R a., Gardner JP, Psaty BM, Jenny NS, Tracy RP, Walston J, Kimura M, and Aviv A. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. *American Journal of Epidemiology*. 2007; 165:14–21.
7. Brouillette S, Singh RK, Thompson JR, Goodall AH, and Samani NJ. White cell telomere length and risk of premature myocardial infarction. *Arteriosclerosis, Thrombosis, and Vascular Biology*.

2003; 23:842–846.

8. Shay JW and Wright WE. Role of telomeres and telomerase in cancer. *Seminars in Cancer Biology*. 2011; 21:349–353.

9. Artandi SE and DePinho R a. Telomeres and telomerase in cancer. *Carcinogenesis*. 2009; 31:9–18.

10. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, and Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. *Lancet*. 2003; 361:393–395.

11. Kimura M, Hjelmborg JVB, Gardner JP, Bathum L, Brimacombe M, Lu X, Christiansen L, Vaupel JW, Aviv A, and Christensen K. Telomere length and mortality: A study of leukocytes in elderly danish twins. *American Journal of Epidemiology*. 2008; 167:799–806.

12. Vera E, Bernardes de Jesus B, Foronda M, Flores JM, and Blasco M a. The rate of increase of short telomeres predicts longevity in mammals. *Cell reports*. 2012; 2:732–737.

13. Mather KA, Jorm AF, Parslow RA, and Christensen H. Is telomere length a biomarker of aging? A review. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*. 2011; 66 A:202–213.

14. Codd V, Mangino M, Harst P van der, Braund PS, Kaiser M, Beveridge AJ, Rafelt S, Moore J, Nelson C, Soranzo N, Zhai G, Valdes AM, Blackburn H, et al. Common variants near TERC are associated with mean telomere length. *Nature genetics*. 2010; 42:197–199.

15. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, Hottenga JJ, Fischer K, Esko T, Surakka I, Broer L, Nyholt DR, Leach IM, et al. Identification of seven loci affecting mean telomere length and their association with disease. *Nature Genetics*. 2013; 45:422–427.

16. Mangino M, Christiansen L, Stone R, Hunt SC, Horvath K, Eisenberg DT a., Kimura M, Petersen I, Kark JD, Herbig U, Reiner a. P, Benetos A, Codd V, et al. DCAF4, a novel gene associated with leucocyte telomere length. *Journal of Medical Genetics*. 2015; 52:157–162.

17. Mangino M, Hwang S-J, Spector TD, Hunt SC, Kimura M, Fitzpatrick AL, Christiansen L, Petersen I, Elbers CC, Harris T, Chen W, Srinivasan SR, Kark JD, et al. Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. *Human Molecular Genetics*. 2012; 21:5385–5394.

18. Holmes E, Wilson ID, and Nicholson JK. Metabolic Phenotyping in Health and Disease. *Cell*. 2008; 134:714–717.

19. Hollywood K, Brison DR, and Goodacre R. Metabolomics: Current technologies and future trends. *Proteomics*. 2006; 6:4716–4723.

20. Zhao J, Zhu Y, Uppal K, Tran VT, Yu T, Lin J, Matsuguchi T, Blackburn E, Jones D, Lee ET, and Howard B V. Metabolic profiles of biological aging in american indians: The strong heart family study. *Aging (Albany, NY)*. 2014; 6:176–186.

21. Petersen a.-KAK, Zeilinger S, Kastenmüller G, Werner RM, Brugger M, Peters A, Meisinger C, Strauch K, Hengstenberg C, Pagel P, Huber F, Mohney RP, Grallert H, et al. Epigenetics meets metabolomics: an epigenome-wide association study with blood serum metabolic traits. *Human Molecular Genetics*. 2014; 23:534–545.

22. Zeilinger S, Kühnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, Weidinger S, Lattka E, Adamski J, Peters A, Strauch K, Waldenberger M, and Illig T. Tobacco Smoking Leads to Extensive Genome-Wide Changes in DNA Methylation. *PLoS*

ONE. 2013; 8:e63812.

23. Dennis E. Diversity of group types, regulation, and function of phospholipase A2. *Journal of Biological Chemistry*. 1994; 269:13057–13060.

24. Farooqui, AA. and Horrocks, LA. *Glycerophospholipids in the Brain*. Springer New York: New York, NY 2007.

25. Cantin B, Brun LD, Gagné C, Murthy MR, Lupien PJ, and Julien P. Alterations in erythrocyte membrane lipid composition and fluidity in primary lipoprotein lipase deficiency. *Biochimica et biophysica acta*. 1992; 1139:25–31.

26. Hulbert A. Life, death and membrane bilayers. *The Journal of experimental biology*. 2003; 206:2303–2311.

27. Rabini R, Moretti N, Staffolani R, Salvolini E, Nanetti L, Franceschi C, and Mazzanti L. Reduced susceptibility to peroxidation of erythrocyte plasma membranes from centenarians. *Experimental Gerontology*. 2002; 37:657–663.

28. Collino S, Montoliu I, Martin FPJ, Scherer M, Mari D, Salvioli S, Bucci L, Ostan R, Monti D, Biagi E, Brigidi P, Franceschi C, and Rezzi S. Metabolic Signatures of Extreme Longevity in Northern Italian Centenarians Reveal a Complex Remodeling of Lipids, Amino Acids, and Gut Microbiota Metabolism. *PLoS ONE*. 2013; 8:1–12.

29. Kamada T and Otsuji S. Lower levels of erythrocyte membrane fluidity in diabetic patients. A spin label study. *Diabetes*. 1983; 32:585–591.

30. Aozaki S. Decreased membrane fluidity in erythrocytes from patients with Crohn's disease. *Gastroenterol.Jpn*. 1989; 24:246–254.

31. Mecocci P, Cherubini A, Beal MF, Cecchetti R, Chionne F, Polidori MC, Romano G, and Senin U. Altered mitochondrial membrane fluidity in AD brain. *Neuroscience Letters*. 1996; 207:129–132.

32. Caprari P, Scuteri A, Salvati AM, Bauco C, Cantafora A, Masella R, Modesti D, Tarzia A, and Marigliano V. Aging and red blood cell membrane: A study of centenarians. *Experimental Gerontology*. 1999; 34:47–57.

33. Zhang H, Forman HJ, and Choi J. Gamma-Glutamyl Transpeptidase in Glutathione Biosynthesis. *Methods in Enzymology*. 2005; 401:468–483.

34. Wu G, Fang Y-Z, Yang S, Lupton JR, and Turner ND. Glutathione metabolism and its implications for health. *The Journal of nutrition*. 2004; 134:489–492.

35. Maher P. The effects of stress and aging on glutathione metabolism. *Ageing Research Reviews*. 2005; 4:288–314.

36. Pandur S, Pankiv S, Johannessen M, Moens U, and Huseby N-E. Gamma-glutamyltransferase is upregulated after oxidative stress through the Ras signal transduction pathway in rat colon carcinoma cells. *Free radical research*. 2007; 41:1376–1384.

37. Whitfield JB. Gamma glutamyl transferase. *Critical reviews in clinical laboratory sciences*. 2001; 38:263–355.


38. Rahman I and MacNee W. Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. *The American journal of physiology*. 1999; 277:L1067–L1088.

39. Manini P, Palma G De, Andreoli R, Goldoni M, Poli D, Lasagni G, and Mutti A. Urinary excretion of 4-vinyl phenol after experimental and occupational exposure to styrene. *Giornale italiano di medicina del lavoro ed ergonomia*. 2003; 25 Suppl:61–62.

40. Hu X-X, Zhong L, Zhang X, Gao Y-M, and Liu B-Z. NLS-RAR α Promotes Proliferation and Inhibits Differentiation in HL-60 Cells. *International Journal of Medical Sciences*. 2014; 11:247–254.

41. Krumsiek J, Mittelstrass K, Do KT, Stückler F, Ried J, Adamski J, Peters A, Illig T, Kronenberg F, Friedrich N, Nauck M, Pietzner M, Mook-Kanamori DO, et al. Gender-specific pathway differences in the human serum metabolome. *Metabolomics*. 2015; 11:1815-1833.
42. Moayyeri A, Hammond CJ, Valdes AM, and Spector TD. Cohort Profile: TwinsUK and healthy ageing twin study. *International journal of epidemiology*. 2013; 42:76–85.
43. Holle R, Happich M, Löwel H, and Wichmann H. KORA - A Research Platform for Population Based Health Research. *Das Gesundheitswesen*. 2005; 67:19–25.
44. Karrasch S, Flexeder C, Behr J, Holle R, Huber RM, Jörres RA, Nowak D, Peters A, Wichmann H-E, Heinrich J, Schulz H, and KORA Study Group. Spirometric reference values for advanced age from a South german population. *Respiration; international review of thoracic diseases*. 2013; 85:210–219.
45. Cawthon RM. Telomere measurement by quantitative PCR. *Nucleic acids research*. 2002; 30:e47.
46. Menni C, Kastenmüller G, Petersen AK, Bell JT, Psatha M, Tsai P-C, Gieger C, Schulz H, Erte I, John S, Brosnan MJ, Wilson SG, Tsaprouni L, et al. Metabolomic markers reveal novel pathways of ageing and early development in human populations. *International journal of epidemiology*. 2013; 42:1111–1119.
47. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates a., Crapo R, Enright P, Grinten CPM van der, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, et al. Standardisation of spirometry. *European Respiratory Journal*. 2005; 26:319–338.
48. Levey AS, Stevens L a, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Lente F Van, Greene T, and Coresh J. A new equation to estimate glomerular filtration rate. *Annals of internal medicine*. 2009; 150:604–612.
49. Grundberg E, Small KS, Hedman ÅK, Nica AC, Buil A, Keildson S, Bell JT, Yang T-P, Meduri E, Barrett A, Nisbett J, Sekowska M, Wilk A, et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. *Nature genetics*. 2012; 44:1084–1089.
50. Tsai P-C, Dongen J Van, Tan Q, Willemsen G, Christiansen L, Boomsma DI, Spector TD, Valdes AM, and Bell JT. DNA methylation changes in the IGF1R gene in birth weight discordant adult monozygotic twins. *Twin Research and Human Genetics*. 2015; (in press)
51. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, and Beck S. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics (Oxford, England)*. 2013; 29:189–196.
52. Cohen, J. *Statistical power analysis for the behavioral sciences*. Routledge: Hillsdale, New Jersey 1988.
53. Tibshirani R. Regression Selection and Shrinkage via the Lasso. *Journal of the Royal Statistical Society B*. 1994; 58:267–288.

SUPPLEMENTAL DATA



Supplemental Figure 1. Forest plots of significant metabolites. The forest plots show effects and confidence intervals for all significant metabolites in the discovery cohort (TwinsUK), the replication cohort (Kora) and the combined meta-analysis. The dashed lines indicate the combined effect after meta-analysis.

Supplemental Table 1. Associations of blood metabolite levels with LTL. The table contains the complete list of all analyzed metabolites and their association with LTL. (indicates FWER<0.05, * indicates FDR <0.05)**

metabolite	pathway	beta [95%CI]	p
1-stearoylglycerophosphoinositol	Lipid	-0.09 [-0.13:-0.05]	1.36×10 ^{-6**}
gamma-glutamyltyrosine	Peptide	-0.09 [-0.12:-0.05]	3.41×10 ^{-6**}
gamma-glutamylphenylalanine	Peptide	-0.08 [-0.12:-0.04]	2.72×10 ^{-5**}
1-palmitoylglycerophosphoinositol	Lipid	-0.08 [-0.13:-0.04]	7.36×10 ^{-5**}
4-vinylphenol sulfate	Xenobiotics	-0.08 [-0.12:-0.04]	7.41×10 ^{-5**}
1-arachidonoylglycerophosphoethanolamine	Lipid	-0.07 [-0.11:-0.03]	2.42×10 ^{-4*}
1-arachidonoylglycerophosphoinositol	Lipid	-0.07 [-0.11:-0.03]	2.76×10 ^{-4*}
1-oleoylglycerophosphoethanolamine	Lipid	-0.07 [-0.10:-0.03]	7.60×10 ^{-4*}
uridine	Nucleotide	0.06 [0.03:0.10]	1.07×10 ^{-3*}
caprylate (8:0)	Lipid	-0.06 [-0.10:-0.02]	1.42×10 ^{-3*}
erythritol	Xenobiotics	-0.06 [-0.09:-0.02]	1.54×10 ^{-3*}
arabinose	Carbohydrate	-0.07 [-0.11:-0.02]	1.75×10 ^{-3*}
ornithine	Amino acid	-0.06 [-0.10:-0.02]	2.14×10 ^{-3*}
heptanoate (7:0)	Lipid	-0.06 [-0.09:-0.02]	3.25×10 ⁻³
pyroglutamine	Amino acid	-0.05 [-0.09:-0.02]	3.54×10 ⁻³
tyrosine	Amino acid	-0.05 [-0.09:-0.02]	5.27×10 ⁻³
laurylcarnitine	Lipid	-0.07 [-0.11:-0.02]	6.70×10 ⁻³
proline	Amino acid	-0.05 [-0.09:-0.01]	7.56×10 ⁻³
malate	Energy	-0.05 [-0.09:-0.01]	7.66×10 ⁻³
caproate (6:0)	Lipid	-0.05 [-0.09:-0.01]	7.66×10 ⁻³
kynurenine	Amino acid	-0.05 [-0.08:-0.01]	1.04×10 ⁻²
pseudouridine	Nucleotide	-0.05 [-0.08:-0.01]	1.30×10 ⁻²
1-palmitoylglycerophosphoethanolamine	Lipid	-0.05 [-0.08:-0.01]	1.31×10 ⁻²
arachidonate (20:4n6)	Lipid	-0.05 [-0.09:-0.01]	1.33×10 ⁻²
3-dehydrocarnitine	Lipid	-0.05 [-0.08:-0.01]	1.41×10 ⁻²
C-glycosyltryptophan	Amino acid	-0.04 [-0.08:-0.01]	1.41×10 ⁻²
1,3,7-trimethylurate	Xenobiotics	-0.06 [-0.11:-0.01]	1.43×10 ⁻²
4-methyl-2-oxopentanoate	Amino acid	0.05 [0.01:0.08]	1.56×10 ⁻²
bilirubin (E,E)	Cofactors and vitamins	0.05 [0.01:0.08]	1.58×10 ⁻²
p-acetamidophenylglucuronide	Xenobiotics	-0.09 [-0.17:-0.02]	1.59×10 ⁻²
glycerol	Lipid	-0.05 [-0.08:-0.01]	1.65×10 ⁻²
1-eicosatrienoylglycerophosphocholine	Lipid	-0.05 [-0.08:-0.01]	1.72×10 ⁻²
lactate	Carbohydrate	-0.05 [-0.08:-0.01]	1.78×10 ⁻²
thromboxane B2	Lipid	-0.04 [-0.08:-0.01]	2.25×10 ⁻²
1-palmitoylglycerol (1-monopalmitin)	Lipid	-0.04 [-0.08:-0.01]	2.34×10 ⁻²
butyrylcarnitine	Lipid	-0.04 [-0.08:-0.01]	2.37×10 ⁻²
2-hydroxyglutarate	Lipid	-0.05 [-0.10:-0.01]	2.38×10 ⁻²
homocitrulline	Amino acid	-0.06 [-0.12:-0.01]	2.74×10 ⁻²
phenylalanine	Amino acid	-0.04 [-0.08:-0.00]	2.74×10 ⁻²
alpha-hydroxyisovalerate	Amino acid	-0.04 [-0.08:-0.00]	3.01×10 ⁻²
CMPF	Lipid	0.04 [0.00:0.07]	3.16×10 ⁻²

biliverdin	Cofactors and vitamins	0.04 [0.00:0.08]	3.47×10 ⁻²
cholesterol	Lipid	-0.04 [-0.07:-0.00]	3.64×10 ⁻²
oleoylcarnitine	Lipid	0.04 [0.00:0.08]	3.83×10 ⁻²
pelargonate (9:0)	Lipid	-0.04 [-0.07:-0.00]	4.00×10 ⁻²
paraxanthine	Xenobiotics	-0.04 [-0.08:-0.00]	4.15×10 ⁻²
3-(cystein-S-yl)acetaminophen	Xenobiotics	-0.09 [-0.18:-0.00]	4.15×10 ⁻²
urate	Nucleotide	-0.04 [-0.07:-0.00]	4.18×10 ⁻²
carnitine	Lipid	-0.04 [-0.08:-0.00]	4.35×10 ⁻²
1-linoleoylglycerophosphoethanolamine	Lipid	-0.04 [-0.08:-0.00]	4.44×10 ⁻²
1-stearoylglycerophosphoethanolamine	Lipid	-0.04 [-0.08:-0.00]	4.46×10 ⁻²
adrenate (22:4n6)	Lipid	-0.04 [-0.08:-0.00]	4.49×10 ⁻²
gamma-glutamylvaline	Peptide	-0.04 [-0.07:-0.00]	4.83×10 ⁻²
threonate	Cofactors and vitamins	0.04 [0.00:0.08]	4.96×10 ⁻²
tetradecanedioate	Lipid	-0.04 [-0.08:0.00]	5.11×10 ⁻²
hyodeoxycholate	Lipid	-0.04 [-0.08:0.00]	5.11×10 ⁻²
2-hydroxystearate	Lipid	-0.04 [-0.07:0.00]	5.18×10 ⁻²
ibuprofen	Xenobiotics	-0.07 [-0.13:0.00]	5.21×10 ⁻²
2-methoxyacetaminophen sulfate	Xenobiotics	-0.08 [-0.17:0.00]	5.22×10 ⁻²
2-hydroxypalmitate	Lipid	-0.04 [-0.07:0.00]	5.24×10 ⁻²
hexadecanedioate	Lipid	-0.04 [-0.08:0.00]	5.36×10 ⁻²
gamma-glutamylthreonine	Peptide	-0.06 [-0.11:0.00]	5.55×10 ⁻²
alanine	Amino acid	-0.04 [-0.07:0.00]	5.73×10 ⁻²
dihomo-linolenate (20:3n3 or n6)	Lipid	-0.04 [-0.07:0.00]	5.88×10 ⁻²
undecanoate (11:0)	Lipid	-0.04 [-0.07:0.00]	6.04×10 ⁻²
glutamate	Amino acid	-0.03 [-0.07:0.00]	6.14×10 ⁻²
glycerate	Carbohydrate	0.03 [-0.00:0.07]	7.26×10 ⁻²
ADpSGEGDFXAEGGGVR	Peptide	0.06 [-0.01:0.12]	7.39×10 ⁻²
naproxen	Xenobiotics	-0.33 [-0.68:0.02]	8.20×10 ⁻²
saccharin	Xenobiotics	-0.06 [-0.12:0.01]	8.32×10 ⁻²
aspartylphenylalanine	Peptide	-0.05 [-0.12:0.01]	8.33×10 ⁻²
beta-hydroxyisovalerate	Amino acid	-0.03 [-0.07:0.00]	8.51×10 ⁻²
propionylcarnitine	Lipid	-0.03 [-0.07:0.00]	8.61×10 ⁻²
7-Hoca	Lipid	-0.03 [-0.07:0.00]	8.69×10 ⁻²
cyclo(leu-pro)	Peptide	-0.04 [-0.09:0.01]	8.73×10 ⁻²
estrone 3-sulfate	Lipid	-0.09 [-0.18:0.01]	8.92×10 ⁻²
benzoate	Xenobiotics	-0.03 [-0.07:0.01]	9.32×10 ⁻²
1-methylxanthine	Xenobiotics	-0.04 [-0.08:0.01]	9.34×10 ⁻²
N-acetylalanine	Amino acid	-0.03 [-0.07:0.01]	9.61×10 ⁻²
pyridoxate	Cofactors and vitamins	0.03 [-0.01:0.07]	9.70×10 ⁻²
4-acetamidobutanoate	Amino acid	-0.03 [-0.07:0.01]	9.80×10 ⁻²
gamma-glutamylleucine	Peptide	-0.03 [-0.07:0.01]	1.01×10 ⁻¹
4-androsten-3beta,17beta-diol disulfate 1	Lipid	-0.03 [-0.07:0.01]	1.07×10 ⁻¹
1-arachidonoylglycerophosphocholine	Lipid	-0.03 [-0.07:0.01]	1.07×10 ⁻¹
1-palmitoylplasménylethanolamine	Lipid	-0.03 [-0.08:0.01]	1.07×10 ⁻¹
2-hydroxyisobutyrate	Amino acid	0.03 [-0.01:0.07]	1.11×10 ⁻¹

cafféine	Xenobiotics	-0.03 [-0.07:0.01]	1.15×10 ⁻¹
3-methyl-2-oxovalerate	Amino acid	0.03 [-0.01:0.07]	1.20×10 ⁻¹
4-acetamidophenol	Xenobiotics	-0.08 [-0.18:0.02]	1.23×10 ⁻¹
N2,N2-dimethylguanosine	Nucleotide	-0.03 [-0.07:0.01]	1.34×10 ⁻¹
cholate	Lipid	0.03 [-0.01:0.08]	1.36×10 ⁻¹
succinylcarnitine	Energy	-0.03 [-0.07:0.01]	1.38×10 ⁻¹
stachydrine	Xenobiotics	0.03 [-0.01:0.07]	1.40×10 ⁻¹
citrate	Energy	0.03 [-0.01:0.06]	1.42×10 ⁻¹
1-palmitoleoylglycerophosphocholine	Lipid	-0.03 [-0.07:0.01]	1.44×10 ⁻¹
gamma-glutamylisoleucine	Peptide	-0.03 [-0.07:0.01]	1.47×10 ⁻¹
phenyllactate	Amino acid	-0.03 [-0.07:0.01]	1.51×10 ⁻¹
hydroxyisovaleroyl carnitine	Amino acid	-0.03 [-0.08:0.01]	1.54×10 ⁻¹
isoleucine	Amino acid	-0.03 [-0.06:0.01]	1.55×10 ⁻¹
palmitate (16:0)	Lipid	-0.03 [-0.07:0.01]	1.58×10 ⁻¹
1,7-dimethylurate	Xenobiotics	-0.03 [-0.07:0.01]	1.59×10 ⁻¹
creatinine	Amino acid	-0.03 [-0.06:0.01]	1.61×10 ⁻¹
3-(3-hydroxyphenyl)propionate	Amino acid	0.07 [-0.03:0.16]	1.64×10 ⁻¹
4-hydroxyhippurate	Xenobiotics	-0.03 [-0.08:0.01]	1.65×10 ⁻¹
N-acetylmornithine	Amino acid	-0.03 [-0.07:0.01]	1.82×10 ⁻¹
N-(2-furoyl)glycine	Xenobiotics	-0.10 [-0.25:0.05]	1.87×10 ⁻¹
palmitoylcarnitine	Lipid	0.02 [-0.01:0.06]	2.02×10 ⁻¹
1-heptadecanoylglycerophosphocholine	Lipid	0.03 [-0.01:0.06]	2.05×10 ⁻¹
histidine	Amino acid	0.02 [-0.01:0.06]	2.08×10 ⁻¹
4-ethylphenylsulfate	Xenobiotics	-0.03 [-0.07:0.02]	2.09×10 ⁻¹
3-methyl-2-oxobutyrate	Amino acid	0.02 [-0.01:0.06]	2.09×10 ⁻¹
phenol sulfate	Amino acid	-0.02 [-0.06:0.01]	2.11×10 ⁻¹
1,5-anhydroglucitol (1,5-AG)	Carbohydrate	-0.02 [-0.06:0.01]	2.12×10 ⁻¹
alpha-tocopherol	Cofactors and vitamins	0.02 [-0.01:0.06]	2.20×10 ⁻¹
2-hydroxyacetaminophen sulfate	Xenobiotics	-0.04 [-0.12:0.03]	2.23×10 ⁻¹
mannose	Carbohydrate	-0.02 [-0.06:0.01]	2.27×10 ⁻¹
glycochenodeoxycholate	Lipid	-0.02 [-0.06:0.02]	2.36×10 ⁻¹
piperine	Xenobiotics	0.02 [-0.02:0.06]	2.38×10 ⁻¹
deoxycholate	Lipid	-0.03 [-0.08:0.02]	2.39×10 ⁻¹
nonadecanoate (19:0)	Lipid	0.02 [-0.01:0.06]	2.41×10 ⁻¹
hippurate	Xenobiotics	0.02 [-0.02:0.06]	2.42×10 ⁻¹
3-indoxyl sulfate	Amino acid	-0.02 [-0.06:0.02]	2.52×10 ⁻¹
bilirubin (Z,Z)	Cofactors and vitamins	0.02 [-0.02:0.06]	2.55×10 ⁻¹
myristate (14:0)	Lipid	-0.02 [-0.06:0.02]	2.56×10 ⁻¹
hexanoylcarnitine	Lipid	-0.02 [-0.06:0.02]	2.61×10 ⁻¹
2-tetradecenoyl carnitine	Lipid	-0.02 [-0.06:0.02]	2.63×10 ⁻¹
myo-inositol	Lipid	-0.02 [-0.06:0.02]	2.70×10 ⁻¹
palmitoyl sphingomyelin	Lipid	-0.02 [-0.06:0.02]	2.70×10 ⁻¹
palmitoleate (16:1n7)	Lipid	-0.02 [-0.06:0.02]	2.74×10 ⁻¹
ursodeoxycholate	Lipid	-0.02 [-0.07:0.02]	2.77×10 ⁻¹
homostachydrine	Xenobiotics	-0.04 [-0.11:0.03]	2.78×10 ⁻¹

lathosterol	Lipid	-0.02 [-0.06:0.02]	2.84×10 ⁻¹
laurate (12:0)	Lipid	-0.02 [-0.06:0.02]	2.86×10 ⁻¹
3-phenylpropionate (hydrocinnamate)	Amino acid	0.02 [-0.02:0.06]	2.86×10 ⁻¹
glutaroyl carnitine	Amino acid	-0.02 [-0.06:0.02]	2.88×10 ⁻¹
DHA (22:6n3)	Lipid	0.02 [-0.02:0.06]	2.92×10 ⁻¹
bradykinin, des-arg(9)	Peptide	0.03 [-0.02:0.08]	3.01×10 ⁻¹
7-methylxanthine	Xenobiotics	0.02 [-0.02:0.07]	3.05×10 ⁻¹
erythrose	Carbohydrate	0.02 [-0.02:0.06]	3.07×10 ⁻¹
epiandrosterone sulfate	Lipid	-0.02 [-0.05:0.02]	3.13×10 ⁻¹
1-stearoylglycerol (1-monostearin)	Lipid	-0.02 [-0.06:0.02]	3.13×10 ⁻¹
10-heptadecenoate (17:1n7)	Lipid	-0.02 [-0.06:0.02]	3.23×10 ⁻¹
glucose	Carbohydrate	-0.02 [-0.06:0.02]	3.37×10 ⁻¹
myristoleate (14:1n5)	Lipid	-0.02 [-0.06:0.02]	3.38×10 ⁻¹
10-undecenoate (11:1n1)	Lipid	0.02 [-0.02:0.06]	3.41×10 ⁻¹
threonine	Amino acid	-0.02 [-0.06:0.02]	3.45×10 ⁻¹
taurochenodeoxycholate	Lipid	-0.02 [-0.06:0.02]	3.45×10 ⁻¹
salicylicuric glucuronide	Xenobiotics	-0.06 [-0.19:0.07]	3.50×10 ⁻¹
5alpha-androstan-3beta,17beta-diol disulfate	Lipid	-0.02 [-0.06:0.02]	3.54×10 ⁻¹
1-methylurate	Xenobiotics	-0.02 [-0.06:0.02]	3.56×10 ⁻¹
dodecanedioate	Lipid	-0.02 [-0.06:0.02]	3.56×10 ⁻¹
GPC	Lipid	-0.02 [-0.06:0.02]	3.57×10 ⁻¹
tryptophan	Amino acid	0.02 [-0.02:0.06]	3.62×10 ⁻¹
1-oleoylglycerol (1-monoolein)	Lipid	-0.02 [-0.07:0.02]	3.64×10 ⁻¹
catechol sulfate	Xenobiotics	-0.02 [-0.06:0.02]	3.64×10 ⁻¹
mannitol	Carbohydrate	-0.02 [-0.06:0.02]	3.71×10 ⁻¹
pantothenate	Cofactors and vitamins	0.02 [-0.02:0.06]	3.74×10 ⁻¹
gamma-tocopherol	Cofactors and vitamins	-0.02 [-0.06:0.02]	3.76×10 ⁻¹
asparagine	Amino acid	0.02 [-0.02:0.05]	3.79×10 ⁻¹
1-stearoylglycerophosphocholine	Lipid	0.02 [-0.02:0.05]	3.83×10 ⁻¹
lysine	Amino acid	-0.02 [-0.05:0.02]	3.83×10 ⁻¹
stearoylcarnitine	Lipid	0.02 [-0.02:0.05]	3.89×10 ⁻¹
2-stearoylglycerophosphocholine	Lipid	0.02 [-0.02:0.05]	3.93×10 ⁻¹
2-methylbutyrocarnitine	Amino acid	-0.02 [-0.05:0.02]	4.03×10 ⁻¹
1,6-anhydroglucose	Carbohydrate	-0.02 [-0.07:0.03]	4.07×10 ⁻¹
glycocholate	Lipid	0.02 [-0.02:0.06]	4.08×10 ⁻¹
leucine	Amino acid	-0.02 [-0.05:0.02]	4.10×10 ⁻¹
15-methylpalmitate (isobar with 2-methylpalmitate)	Lipid	-0.02 [-0.06:0.03]	4.14×10 ⁻¹
acetylphosphate	Energy	-0.01 [-0.05:0.02]	4.31×10 ⁻¹
5alpha-pregnan-3beta,20alpha-diol disulfate	Lipid	0.02 [-0.03:0.06]	4.42×10 ⁻¹
cysteine	Amino acid	-0.01 [-0.05:0.02]	4.43×10 ⁻¹
phenylacetate	Amino acid	0.02 [-0.03:0.06]	4.54×10 ⁻¹
n-Butyl Oleate	Lipid	0.02 [-0.03:0.07]	4.56×10 ⁻¹
cis-4-decenoyl carnitine	Lipid	-0.02 [-0.06:0.03]	4.58×10 ⁻¹
creatine	Amino acid	0.01 [-0.02:0.05]	4.67×10 ⁻¹
3-(4-hydroxyphenyl)lactate	Amino acid	-0.01 [-0.05:0.02]	4.74×10 ⁻¹

7-methylguanine	Nucleotide	-0.02 [-0.06:0.03]	4.88×10 ⁻¹
citrulline	Amino acid	-0.01 [-0.05:0.02]	4.93×10 ⁻¹
DHEA-S	Lipid	-0.01 [-0.04:0.02]	5.03×10 ⁻¹
pentadecanoate (15:0)	Lipid	-0.01 [-0.05:0.03]	5.10×10 ⁻¹
5-dodecenoate (12:1n7)	Lipid	-0.01 [-0.05:0.03]	5.13×10 ⁻¹
4-androsten-3beta,17beta-diol disulfate 2	Lipid	-0.01 [-0.05:0.03]	5.15×10 ⁻¹
arginine	Amino acid	0.01 [-0.03:0.05]	5.19×10 ⁻¹
linoleate (18:2n6)	Lipid	-0.01 [-0.05:0.03]	5.27×10 ⁻¹
octanoylcarnitine	Lipid	-0.01 [-0.05:0.03]	5.32×10 ⁻¹
atenolol	Xenobiotics	-0.06 [-0.25:0.13]	5.39×10 ⁻¹
phenylalanylphenylalanine	Peptide	0.02 [-0.04:0.08]	5.40×10 ⁻¹
tryptophan betaine	Amino acid	0.01 [-0.03:0.05]	5.42×10 ⁻¹
androsterone sulfate	Lipid	-0.01 [-0.05:0.02]	5.44×10 ⁻¹
N-acetylthreonine	Amino acid	-0.01 [-0.05:0.03]	5.46×10 ⁻¹
2-hydroxyhippurate (salicylurate)	Xenobiotics	0.02 [-0.04:0.08]	5.65×10 ⁻¹
glycerol 2-phosphate	Xenobiotics	0.01 [-0.03:0.05]	5.90×10 ⁻¹
dihomo-linoleate (20:2n6)	Lipid	-0.01 [-0.05:0.03]	5.94×10 ⁻¹
valine	Amino acid	-0.01 [-0.05:0.03]	5.94×10 ⁻¹
carbamazepine	Xenobiotics	0.12 [-0.31:0.55]	6.01×10 ⁻¹
3-hydroxybutyrate (BHBA)	Lipid	0.01 [-0.03:0.05]	6.05×10 ⁻¹
N1-methyladenosine	Nucleotide	-0.01 [-0.05:0.03]	6.16×10 ⁻¹
betaine	Amino acid	0.01 [-0.03:0.05]	6.21×10 ⁻¹
decanoylcarnitine	Lipid	0.01 [-0.03:0.05]	6.21×10 ⁻¹
N-acetylglycine	Amino acid	0.01 [-0.03:0.05]	6.28×10 ⁻¹
isovalerate	Lipid	-0.01 [-0.05:0.03]	6.34×10 ⁻¹
allantoin	Nucleotide	-0.01 [-0.05:0.03]	6.40×10 ⁻¹
chiro-inositol	Lipid	0.02 [-0.05:0.08]	6.42×10 ⁻¹
salicylate	Xenobiotics	-0.01 [-0.08:0.05]	6.47×10 ⁻¹
glycine	Amino acid	0.01 [-0.03:0.05]	6.50×10 ⁻¹
serine	Amino acid	0.01 [-0.03:0.05]	6.56×10 ⁻¹
cotinine	Xenobiotics	0.02 [-0.08:0.12]	6.65×10 ⁻¹
dimethylarginine (SDMA + ADMA)	Amino acid	0.01 [-0.03:0.05]	6.78×10 ⁻¹
hypoxanthine	Nucleotide	-0.01 [-0.05:0.03]	6.89×10 ⁻¹
theobromine	Xenobiotics	-0.01 [-0.05:0.03]	6.90×10 ⁻¹
erythronate	Carbohydrate	0.01 [-0.03:0.05]	6.90×10 ⁻¹
taurocholate	Lipid	0.01 [-0.04:0.06]	6.92×10 ⁻¹
alpha-ketoglutarate	Energy	0.01 [-0.03:0.05]	7.12×10 ⁻¹
stearidonate (18:4n3)	Lipid	-0.01 [-0.04:0.03]	7.13×10 ⁻¹
2-palmitoylglycerophosphocholine	Lipid	-0.01 [-0.04:0.03]	7.32×10 ⁻¹
eicosenoate (20:1n9 or 11)	Lipid	0.01 [-0.03:0.04]	7.44×10 ⁻¹
pyruvate	Carbohydrate	0.01 [-0.03:0.04]	7.54×10 ⁻¹
valerate	Lipid	-0.01 [-0.06:0.04]	7.55×10 ⁻¹
fructose	Carbohydrate	0.01 [-0.03:0.04]	7.57×10 ⁻¹
EPA	Lipid	0.01 [-0.03:0.04]	7.58×10 ⁻¹
stearate (18:0)	Lipid	-0.01 [-0.04:0.03]	7.61×10 ⁻¹

octadecanedioate	Lipid	0.01 [-0.03:0.04]	7.73×10 ⁻¹
urea	Amino acid	-0.01 [-0.04:0.03]	7.75×10 ⁻¹
indoleacetate	Amino acid	0.01 [-0.03:0.04]	7.76×10 ⁻¹
cortisone	Lipid	-0.01 [-0.04:0.03]	7.76×10 ⁻¹
levulinate (4-oxovalerate)	Amino acid	0.01 [-0.03:0.04]	7.80×10 ⁻¹
oleate (18:1n9)	Lipid	-0.01 [-0.04:0.03]	7.82×10 ⁻¹
margarate (17:0)	Lipid	-0.01 [-0.04:0.03]	7.83×10 ⁻¹
1-oleoylglycerophosphocholine	Lipid	0.01 [-0.03:0.04]	7.87×10 ⁻¹
tauroolithocholate 3-sulfate	Lipid	-0.00 [-0.05:0.04]	8.10×10 ⁻¹
leucylleucine	Peptide	-0.01 [-0.06:0.05]	8.21×10 ⁻¹
ADSGEGDFXAEGGGVR	Peptide	0.01 [-0.04:0.05]	8.23×10 ⁻¹
3-methoxytyrosine	Amino acid	-0.00 [-0.05:0.04]	8.26×10 ⁻¹
2-hydroxybutyrate (AHB)	Amino acid	0.00 [-0.03:0.04]	8.29×10 ⁻¹
methionine	Amino acid	0.00 [-0.03:0.04]	8.31×10 ⁻¹
pipecolate	Amino acid	-0.00 [-0.04:0.03]	8.33×10 ⁻¹
2-oleoylglycerophosphocholine	Lipid	0.00 [-0.03:0.04]	8.36×10 ⁻¹
1-linoleoylglycerophosphocholine	Lipid	0.00 [-0.03:0.04]	8.40×10 ⁻¹
scyllo-inositol	Lipid	0.00 [-0.04:0.05]	8.42×10 ⁻¹
glutamine	Amino acid	-0.00 [-0.04:0.03]	8.44×10 ⁻¹
indolelactate	Amino acid	-0.00 [-0.04:0.03]	8.47×10 ⁻¹
heme	Cofactors and vitamins	0.00 [-0.04:0.05]	8.56×10 ⁻¹
2-aminobutyrate	Amino acid	0.00 [-0.03:0.04]	8.58×10 ⁻¹
10-nonadecenoate (19:1n9)	Lipid	-0.00 [-0.04:0.03]	8.78×10 ⁻¹
1-myristoylglycerophosphocholine	Lipid	-0.00 [-0.04:0.03]	8.80×10 ⁻¹
thymol sulfate	Xenobiotics	-0.00 [-0.06:0.05]	8.81×10 ⁻¹
pro-hydroxy-pro	Peptide	0.00 [-0.04:0.04]	8.82×10 ⁻¹
trans-4-hydroxyproline	Amino acid	0.00 [-0.04:0.04]	8.86×10 ⁻¹
cortisol	Lipid	0.00 [-0.04:0.04]	8.87×10 ⁻¹
5-oxoproline	Amino acid	0.00 [-0.04:0.04]	8.91×10 ⁻¹
threitol	Carbohydrate	-0.00 [-0.04:0.03]	8.91×10 ⁻¹
G3P	Lipid	0.00 [-0.03:0.04]	9.01×10 ⁻¹
serotonin	Amino acid	-0.00 [-0.05:0.04]	9.04×10 ⁻¹
acetylcarnitine	Lipid	-0.00 [-0.04:0.04]	9.04×10 ⁻¹
isobutyrylcarnitine	Amino acid	0.00 [-0.04:0.04]	9.05×10 ⁻¹
HWESASXX	Peptide	-0.00 [-0.04:0.03]	9.10×10 ⁻¹
bilirubin (E,Z or Z,E)	Cofactors and vitamins	0.00 [-0.04:0.05]	9.15×10 ⁻¹
metoprolol acid metabolite	Xenobiotics	-0.01 [-0.19:0.18]	9.24×10 ⁻¹
1-docosahexaenoylglycerophosphocholine	Lipid	0.00 [-0.04:0.04]	9.37×10 ⁻¹
ergothioneine	Xenobiotics	-0.00 [-0.05:0.05]	9.38×10 ⁻¹
p-cresol sulfate	Amino acid	0.00 [-0.04:0.04]	9.41×10 ⁻¹
indolepropionate	Amino acid	0.00 [-0.04:0.04]	9.42×10 ⁻¹
choline	Lipid	0.00 [-0.04:0.04]	9.43×10 ⁻¹
isovalerylcarnitine	Amino acid	-0.00 [-0.04:0.04]	9.45×10 ⁻¹
2-linoleoylglycerophosphocholine	Lipid	-0.00 [-0.04:0.04]	9.46×10 ⁻¹
docosapentaenoate (n3 DPA; 22:5n3)	Lipid	0.00 [-0.04:0.04]	9.47×10 ⁻¹

1-palmitoylglycerophosphocholine	Lipid	-0.00 [-0.04:0.04]	9.50×10^{-1}
phosphate	Energy	-0.00 [-0.04:0.04]	9.53×10^{-1}
phenylacetylglutamine	Amino acid	0.00 [-0.04:0.04]	9.60×10^{-1}
3-methylxanthine	Xenobiotics	0.00 [-0.04:0.05]	9.61×10^{-1}
DSGEGDFXAEGGGVR	Peptide	-0.00 [-0.05:0.05]	9.62×10^{-1}
xanthine	Nucleotide	-0.00 [-0.04:0.04]	9.80×10^{-1}
gamma-glutamylglutamine	Peptide	-0.00 [-0.04:0.04]	9.99×10^{-1}